Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT06202755
PHASE3

Ticagrelor Versus Cilostazol in Large-vessel Ischemic Stroke

Sponsor: Kafrelsheikh University

View on ClinicalTrials.gov

Summary

Along with the current clinical trial, the efficacy and safety of 180 mg loading dose of ticagrelor administered within 24 hours of first-ever large-vessel ischemic stroke compared to 200 mg cilostazol were assessed through NIHSS, mRS, and possible adverse effects.

Official title: Ticagrelor Versus Cilostazol in Ischemic Stroke

Key Details

Gender

All

Age Range

18 Years - 75 Years

Study Type

INTERVENTIONAL

Enrollment

580

Start Date

2024-03-30

Completion Date

2025-07-12

Last Updated

2024-08-20

Healthy Volunteers

No

Conditions

Interventions

DRUG

Ticagrelor 90 MG

Efficacy and safety of 180 mg loading dose of ticagrelor administered within 24 hours of first-ever ischemic stroke followed by 90 mg bid for 3 months will be assessed through NIHSS, mRS, duration of hospital stay, new ischemic stroke, and possible adverse effects.

DRUG

Cilostazol 100 MG

Efficacy and safety of 200 mg clopidogrel followed by 100 mg twice daily for 3 months will be assessed through NIHSS, mRS, duration of hospital stay, new ischemic stroke, and possible adverse effects.

Locations (1)

Kafr Elsheikh University Hospital

Kafr ash Shaykh, Egypt